Recap: Reneo Pharmaceuticals Q3 Earnings
Portfolio Pulse from Benzinga Insights
Reneo Pharmaceuticals (NASDAQ:RPHM) reported Q3 earnings with an EPS of $-0.57, which was in line with estimates. Revenue remained unchanged from the same period last year. The previous quarter's earnings miss resulted in a 4.31% share price drop the following day.
November 13, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Reneo Pharmaceuticals reported Q3 earnings with an EPS of $-0.57, meeting estimates, and no change in year-over-year revenue. Previously, an earnings miss led to a stock price decline.
Since Reneo Pharmaceuticals' earnings were in line with expectations and there was no change in revenue, the short-term impact on the stock price is likely to be neutral. However, given the previous quarter's negative reaction to an earnings miss, investors may be cautious, which could lead to some volatility.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100